PDCD1 and non-small cell lung carcinoma: However, a recent phase II trial (50) has revealed that pembrolizumab, an anti-PD-1 inhibitor, showed consistent brain and extra-cerebral responses in patients with NSCLC, indicating that immunotherapy can be active in patients with active BMs.